Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

Back to Top

Register now for IPA's upcoming Journal Club!



Lecanemab in Early Alzheimer’s Disease

 [ September 26th, 2023 at 7:00 AM CDT ]

See your local time here.

Click here to register for this IPA event.

Dr. Chertkow will present on the article Lecanemab in Early Alzheimer’s Disease (C.H. van Dyck, et al). You can review this open access article here.

By the end of the session participants will be able to:

  1. Describe the evidence from this study for lecanemab in Alzheimer’s Disease
  2. List facilitators and barriers to using lecanmab in the clinical setting
  3. List side effects of lecanemab

Is there hope in the treatment of Alzheimer’s Disease? Lecanemab has been approved by the FDA in the United States of America, and other countries may follow. In this iteration of the IPA Journal Club, we will look carefully at the 2023 New England Journal of Medicine study and have a robust discussion.

Dr. Chertkow is a cognitive neurologist at the Baycrest Health Sciences Centre. He is a Senior Scientist and Chair in Cognitive Neurology and Innovation at Baycrest’s Rotman Research Institute. He is a Professor in the Dept. of Medicine (Neurology) at University of Toronto. At Baycrest he is also director of the new Bank Family Clinical Trials Research Unit and the Kimel Family Centre for Brain Health. His major areas of research interest include early diagnosis of Alzheimer’s disease, and therapy of dementia using neuromodulation approaches such as transcranial direct current stimulation. Dr. Chertkow is Scientific Director for the Canadian Consortium on Neurodegeneration in Aging (CCNA), a national organization established by the Canadian government via CIHR and partners.


Robert Madan MD FRCPC Baycrest, Toronto IPA Products & Services Committee Canada

Please don't hesitate to contact the IPA Secretariat with any questions or concerns prior to the event.

Facebook  LinkedIn  Twitter  Instagram

IPA Secretariat: 555 E. Wells Street, Suite 1100 | Milwaukee, WI 53202 Tel: (414) 918.9889 | Fax: (414) 276.3349 Web: | Email:


Acadia Pharmaceuticals Avanir Pharmaceuticals Cambridge University Press